Genetic Solutions > POC

POC Products of Conception

Studies fetal tissue from a lost pregnancy to investigate whether the miscarriage was the result of chromosomal aneuploidy

Overview

POC
Benefits
Indications

What is POC?

The POC test analyzes fetal tissues from a miscarriage to determine if the lost pregnancy was the result of a chromosomal aneuploidy.
This test can provide you an important information about the possible causes of your patient’s miscarriage to help them to plan any future pregnancy.

What is the procedure?

Why use POC test?

The genetic study of fetal tissue is a valuable tool to determine the cause of the miscarriage, which enables appropriate reproductive counseling for the couple.

Results are obtained in 86,4% of cases.
Results are available in 10-12 working days as cell culture is not required.
24 chromosomes are screened to identify the reason for miscarriage.
Can be performed on twin pregnancies.
Our test discerns between maternal and fetal tissue using DNA fingerprinting (STR Technology).
NGS has higher resolution than a conventional karyotype.

Who should use POC test?

POC is recommended for all couples who have suffered a miscarriage, but is essential for couples who have experienced recurring spontaneous abortions and those undergoing assisted reproduction treatments.

Test Limitations

This technique does not detect balanced structural chromosomal abnormalities and may not detect: low-level mosaic aneuploidy, triploid/tetraploid chromosomes, uniparental disomy, deletions or duplications under 10 Mb.

Documentation

Specialists documents

Relevant related studies:

Campos-Galindo I, García-Herrero S, Martínez-Conejero JA, Ferro J, Simón C, Rubio C. Molecular analysis of products of conception obtained by hysteroembryoscopy from infertile couples. J Assist Reprod Genet. 2015 May;32(5):839-48. doi: 10.1007/s10815-015-0460-z. Epub 2015 Mar 17. PMID: 25779005; PMCID: PMC4429442.
Martínez MC, Méndez C, Ferro J, Nicolás M, Serra V, Landeras J. Cytogenetic analysis of early nonviable pregnancies after assisted reproduction treatment. Fertil Steril. 2010 Jan;93(1):289-92. doi: 10.1016/j.fertnstert.2009.07.989. Epub 2009 Sep 11. PMID: 19748088.
Al-Asmar N, Oral presentation ESHRE 2019. Simón, C., & Rubio, C. (Eds.). (2022). Handbook of Genetic Diagnostic Technologies in Reproductive Medicine: Improving Patient Success Rates and Infant Health (2nd ed.). CRC Press. https://doi.org/10.1201/9781003024941
Colley E, Devall AJ, Williams H, Hamilton S, Smith P, Morgan NV, et al. Cell-Free DNA in the Investigation of Miscarriage. J Clin Med. 2020;9(11).
Clark-Ganheart CA, Fries MH, Leifheit KM, Jensen TJ, Moreno-Ruiz NL, Ye PP, et al. Use of cell-free DNA in the investigation of intrauterine fetal demise and miscarriage. Obstet Gynecol. 2015;125(6):1321-9.
Yaron Y, Pauta M, Badenas C, Soler A, Borobio V, Illanes C, et al. Maternal plasma genome-wide cell-free DNA can detect fetal aneuploidy in early and recurrent pregnancy loss and can be used to direct further workup. Hum Reprod. 2020;35(5):1222-9.
Schlaikjær Hartwig T, Ambye L, Gruhn JR, Petersen JF, Wrønding T, Amato L, et al. Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study. Lancet. 2023;401(10378):762-71.
Peng S, Bhatt S, Borrell A, Yaron Y. Economic impact of using maternal plasma cell-free DNA testing to guide further workup in recurrent pregnancy loss. Prenat Diagn. 2021;41(10):1215-21.
Balaguer N, Rodrigo L, Mateu-Brull E, Campos-Galindo I, Al-Asmar N, Rubio C, Milán M. Cell-free DNA-based non-invasive approach for the diagnosis of clinical miscarriage: a retrospective study. BJOG.2023 (Under review).

Campos-Galindo I, et al. J Assist Reprod Genet 2015; 32:839-48

Martínez MC, et al. Fertil Steril 2010;93:289-92.

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.